Back to home
REGULATORYApril 1, 2026·6 min read
Unlearn.AI Synthetic Control Arms Get Favorable FDA Guidance
The FDA issues draft guidance acknowledging AI-generated synthetic control arms as acceptable in certain clinical trial contexts, potentially reducing trial sizes by 20-30% and accelerating rare disease drug development.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.